A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting

The British Journal of Dermatology
Klazien Matter-WalstraMatthias Schwenkglenks

Abstract

The treatment of patients with metastatic melanomas that harbour BRAF V600E or V600K mutations with trametinib plus dabrafenib appears to be superior to treatment with vemurafenib alone. This treatment regimen is likely to become available in Switzerland in the near future. To determine the cost-effectiveness of trametinib plus dabrafenib. A Markov cohort simulation was conducted to model the clinical course of typical patients with metastatic melanoma. Information on response rates, clinical condition and follow-up treatments were derived and transition probabilities estimated based on the results of a clinical trial that compared treatment with trametinib plus dabrafenib vs. vemurafenib alone. Treatment with trametinib plus dabrafenib was estimated to cost an additional CHF199 647 (Swiss francs) on average and yield a gain of 0·52 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of CHF385 603 per QALY. Probabilistic sensitivity analyses showed that a willingness-to-pay threshold of CHF100 000 per QALY would not be reached at the current US price of trametinib. The introduction of trametinib in Switzerland at US market prices for the treatment of metastatic BRAF V600-mutated melanoma wi...Continue Reading

References

Nov 21, 2007·Current Medical Research and Opinion·S IannazzoL Pradelli
Dec 20, 2011·Swiss Medical Weekly·R DummerUNKNOWN Project Group Melanoma of the Swiss Group for Clinical Cancer Research
May 5, 2012·Journal of Translational Medicine·Paolo A AsciertoNicola Mozzillo
Mar 15, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayF Bray
Feb 8, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SchadendorfC Robert
Mar 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander M Menzies, Georgina V Long
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertDirk Schadendorf
Dec 5, 2014·Expert Review of Clinical Pharmacology·Mark M Awad, Ryan J Sullivan
Jan 1, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Clement Chung, Sean Reilly
Jan 24, 2015·Journal of Managed Care & Specialty Pharmacy·Bhakti ArondekarNicole Meyer
Feb 5, 2015·Expert Opinion on Drug Safety·Lesly A DossettJonathan S Zager
Feb 25, 2015·Frontiers in Immunology·Mariana Aris, María Marcela Barrio
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SchadendorfC Robert

❮ Previous
Next ❯

Citations

Feb 8, 2016·European Journal of Internal Medicine·Dario Maratea, Francesca Venturini
Mar 22, 2016·Expert Opinion on Pharmacotherapy·Amélie Boespflug, Luc Thomas
Jan 24, 2018·The British Journal of Dermatology·T Wiesner, A Zbyszewski
Nov 3, 2015·The British Journal of Dermatology·D F SebaratnamP Fernández-Peñas
Jan 21, 2016·The British Journal of Dermatology·K Matter-WalstraM Schwenkglenks
Feb 28, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·M KrenselM Augustin
Nov 9, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·M KrenselM Augustin
Nov 26, 2019·PharmacoEconomics·Claire GorryMichael Barry
May 30, 2017·PharmacoEconomics·Darío Rubio-RodríguezCarlos Rubio-Terrés

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Konstantin J DedesThomas D Szucs
The New England Journal of Medicine
Hiroyuki Morita, Ryozo Nagai
© 2021 Meta ULC. All rights reserved